Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2008-12-22
2009-10-06
Nickol, Gary B (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Reexamination Certificate
active
07598029
ABSTRACT:
The invention provides a novel in vitro method for identifying HIV-1 protease inhibitors with reduced potential for inducing metabolic abnormalities. The invention further provides diagnostic methods for identifying patients who may be at risk of developing metabolic abnormalities subsequent to the administration of an HIV-1 protease inhibitor. The invention also provides novel polynucleotides associated with the incidence of HIV-1 protease inhibitor induced metabolic abnormalities. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. The invention further relates to diagnostic methods for using these novel polynucleotides in the diagnosis, treatment, and/or prevention of HIV-1 protease inhibitor induced metabolic abnormalities.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5837832 (1998-11-01), Chee et al.
patent: 5849911 (1998-12-01), Fässler et al.
patent: 5856104 (1999-01-01), Chee et al.
patent: 5856174 (1999-01-01), Lipshutz et al.
patent: 5858659 (1999-01-01), Sapolsky et al.
patent: 5874219 (1999-02-01), Rava et al.
patent: 6087383 (2000-07-01), Singh et al.
patent: 6440707 (2002-08-01), Kwok et al.
patent: 6458540 (2002-10-01), Ramberg
patent: 2005/0256202 (2005-11-01), Kim et al.
patent: WO89/11548 (1989-11-01), None
patent: WO93/22456 (1993-11-01), None
patent: WO95/11995 (1995-05-01), None
patent: WO99/07865 (1999-02-01), None
patent: WO00/64920 (2000-11-01), None
SNP Cluster Report: RS3219177, Entry Date Jul. 2, 2002.
Kamin, et al., “Resistin Levels in Human Immunodeficiency Virus-Infected Patients with Lipoatrophy Decrease in Response to Rosiglitazone”, J. Clin. Endocrinology & Metabolism, vol. 90 (6), pp. 3423-3426 (2005).
Ranade, et al., “A Single Nucleotide Polymorphism in the Resistin Gene Is Associated with Adverse Metabolic Changes on HAART: An Exploratory Pharmacogenetic Association Study of A5005s, the Metabolic Sub-study of ACTG 384”, 13th Conference on Retroviruses and Opportunistic Infections, Feb. 5, 2006, Session 131—“Genomic Mechanisms of Metabolic Complications”.
Adeghate, E., “An update on the biology and physiology of resistin”, Cell. Mol. Life Sci., vol. 61, pp. 2485-2496 (2004).
Alderborn, A., “Determination of Single-Nucleotide Polymorphisms by Realtime Pyrophosphate DNA Sequencing”, Genome Research, vol. 10, pp. 1249-1258 (2000).
Armstrong, B. et al., “Suspension Arrays for High Throughput, Multiplexed Single Nucleotide Polymorphism Genotyping”, Cytometry, vol. 40, pp. 102-108 (2000).
Ausubel, F. et al., “Hybridization Analysis of DNA Blots”, Current Protocols in Molecular Biology, vol. 1, pp. 2.10.1-2.10.16 (1995).
Ausubel, F. et al., “Directed Mutagenesis Using the Polymerase Chain Reaction”, Current Protocols in Molecular Biology, vol. 1, pp. 8.5.1-8.5.9 (1995).
Azuma, K. et al., “Novel Resistin Promoter Polymorphisms: Association with Serum Resistin Level in Japanese Obese Individuals”, Horm Metab Res., vol. 36, pp. 564-570 (2004).
Banér, J. et al., “More keys to padlock probes: mechanisms for high-throughput nucleic acid analysis”, Current Opinion in Biotechnology, vol. 12, pp. 11-15 (2001).
Banér, J. et a., “Signal amplification of padlock probes by rolling circle replication”, Nucleic Acids Research, vol. 26(22), pp. 5073-5078 (1998).
Banerjee, R. et al., “Resistin: molecular history and prognosis”, J. Mol. Med., vol. 81, pp. 218-226 (2003).
Banerjee, R. et al., “Regulation of Fasted Blood Glucose by Resistin”, Science, vol. 303, pp. 1195-1198 (2004).
Bartlett, R. et al., “In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide”, Nature Biotechnology, vol. 18, pp. 615-622 (2000).
Beaudet, L. et al., “Homogeneous Assays for Single-Nucleotide Polymorphism Typing Using AlphaScreen”, Genome Research, vol. 11, pp. 600-608 (2001).
Bennett, M. et al., “Correspondence Between a Mammalian Spliceosome Component and an Essential Yeast Splicing Factor”, Science, vol. 262, pp. 105-108 (1993).
Berg, J. et al., “Lessons from Zinc-binding Peptides”, Annu. Rev. Biophys. Biomol. Struct., vol. 26, pp. 357-371 (1997).
Bouchie, A. et al., “Confirmant to sell protein data” Business and Regulatory News, Nature Biotechnology, vol. 19, pp. 703-705 (2001).
Bray, M. et al., “High-Throughput Multiplex SNP Genotyping with MALDI-TOF Mass Spectrometry: Practice, Problems and Promise”, Human Mutation, vol. 17, pp. 296-304 (2001).
Brown, P. et al., “Exploring the new world of the genome with DNA microarrays”, Nature Genetics supplement, vol. 21, pp. 33-37 (1999).
Cai, H. et al., “Flow Cytometry-Based Minisequencing: A New Platform for High-Throughput Single-Nucleotide Polymorphism Scoring”, ERRATUM, Genomics, vol. 69, pp. 395 (2000).
Calza, L. et al., “Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients”, J. of Antimicrobial Chemotherapy, vol. 53, pp. 10-14 (2004).
Cargill, M. et al., “Characterization of single-nucleotide polymorphisms in coding regions of human genes”, Nature genetics, vol. 22, pp. 231-238 (1999).
Carr, A., “HIV Protease Inhibitor-Related Lipodystrophy Syndrome”, Clinical Infectious Diseases, vol. 30(Suppl 2), pp. S135-S142 (2000).
Carr, A., “HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management”, AIDS, vol. 17(suppl 1), pp. S141-S148 (2003).
Chan, W. et al., Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection, Science, vol. 281, pp. 2016-2018 (1998).
Chen, X. et al., “Fluorescence energy transfer detection as a homogeneous DNA diagnostic method”, PNAS, vol. 94, pp. 10756-10761 (1997).
Chen, J. et al., “A Microsphere-Based Assay for Multiplexed Single Nucleotide Polymorphism Analysis Using Single Base Chain Extension”, Genome Research, vol. 10, pp. 549-557 (2000).
Chen, X. et al., “Fluorescence Polarization in Homogeneous Nucleic Acid Analysis”, Genome Research, vol. 9, pp. 492-498 (1999).
Cho, Y. et al., “Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans”, Diabetolgia, vol. 47, pp. 559-565 (2004).
Chou, K.C. et al., “Predicting Human Immunodeficiency Virus Protease Cleavage Sites in Proteins by a Discriminant Function Method”, Proteins: Structure, Function, and Genetics, vol. 24, pp. 51-72 (1996).
Clark, A. et al., “Haplotype Structure and Population Genetic Inferences from Nucleotide-sequence Variation in Human Lipoprotein Lipase”, Am. J. Hum. Genet., vol. 63, pp. 595-612 (1998).
Clark, A., “Inference of Haplotypes from PCR-amplified Samples of Diploid Populations”, Mol. Biol. Evol., vol. 7(2), pp. 111-122 (1990).
Cohen, C. et al., “Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial”, Current Medical Research and Opinions, vol. 21(10), pp. 1683-1692 (2005).
Conneely, K. et al., “Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects”, Diabetologia, vol. 47, pp. 1782-1788 (2004).
Criqui, M., “Triglycerides and cardiovascular disease”, European Heart Journal, vol. 19, Supplement A, pp. A36-A39 (1998).
Dash, C. et al., “Aspartic Peptidase Inhibitors: I
Geese William J.
Ranade Koustubh
Bristol--Myers Squibb Company
D'Amico Stephen C.
Kinsey White Nicole
Nickol Gary B
LandOfFree
Method for identifying HIV-1 protease inhibitors with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying HIV-1 protease inhibitors with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying HIV-1 protease inhibitors with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061302